Trials / Completed
CompletedNCT05857085
Novel Therapeutics and Endothelial Dysfunction in T1DM Patients
Impact of Additional Treatment With Empagliflozin or Semaglutide on Endothelial Function and Other Clinical Parameters and Biomarkers in T1DM Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- General and Teaching Hospital Celje · Academic / Other
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim of study is impact of additional treatment with new antidiabetic drugs (semaglutide or empagliflozine) compared to control group in T1DM patients - impact on endothelial function measured by FMD and FPF, arterial stiffness - measured by PWV, inflammatory biomarkers, markers of oxidative stress and endothelial progenitor cells (CD 34+/VDRL2, CD 133+/VDRL2) and correlation with glucovariability or time in range, measured with CGM system.
Conditions
- Endothelial Dysfunction
- Diabetes Mellitus, Type 1
- Biomarkers
- Endothelial Progenitor Cells
- SGLT 2 Inhibitors
- Incretins
- Glucose Excursions
- FMD
- FPF
- Arterial Stiffness
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Semaglutide Pen Injector [Ozempic] | GLP 1 agonist |
| DRUG | Empagliflozin 10 MG | SGLT 2 inhibitor |
Timeline
- Start date
- 2021-12-15
- Primary completion
- 2022-03-10
- Completion
- 2023-04-20
- First posted
- 2023-05-12
- Last updated
- 2023-05-12
Locations
1 site across 1 country: Slovenia
Source: ClinicalTrials.gov record NCT05857085. Inclusion in this directory is not an endorsement.